ADRB2 serves as a novel biomarker and attenuates alcoholic hepatitis via the SIRT1/PGC-1α/PPARα pathway: integration of WGCNA, machine learning and experimental validation
This study points to ADRB2 as a promising biomarker with potential diagnostic and prognostic value in clinical cohort data. In addition, in AH patients, <i>in vivo</i> and <i>in vitro</i> experiments confirmed the key role of ADRB2 in the progression of AH. These findings suggest that ADRB2 may alleviate AH by activating the SIRT1/PPARα/PGC-1α pathway. This finding provides a new perspective for the diagnosis and treatment of AH.
Authors
- Hung‐Chun Fu (ORCID: https://orcid.org/0000-0002-0660-9349)
- Ping Qiu (ORCID: https://orcid.org/0000-0003-3497-907X)
- Yu Du (ORCID: https://orcid.org/0000-0002-6837-1567)
- Qihan Luo (ORCID: https://orcid.org/0000-0002-2743-1332)
- Fang‐Ming Chen (ORCID: https://orcid.org/0000-0002-5427-6868)
- Kanglu Zhao
- Minxia Chen
- Qing Ma (ORCID: https://orcid.org/0000-0001-6453-6603)
- Song Li (ORCID: https://orcid.org/0000-0001-7753-3700)
- Honghao Yan
- Lisha Zhao (ORCID: https://orcid.org/0000-0001-6941-5253)
- Yu‐Fan Chen (ORCID: https://orcid.org/0009-0004-0280-8318)
- Shuo Huang (ORCID: https://orcid.org/0000-0003-3055-7427)
- He Jiang (ORCID: https://orcid.org/0000-0002-2376-6688)
- Jiang Qiu
- Zongyuan Li (ORCID: https://orcid.org/0009-0000-0832-311X)
Institutions
- Zhejiang Chinese Medical University (CN)
- Hangzhou Normal University (CN)
- Tongde Hospital of Zhejiang Province (CN)
- The Third Affiliated Hospital of Zhejiang Chinese Medical University (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2024-11-21
- DOI
- https://doi.org/10.3389/fphar.2024.1423031
- Citations
- 1
- Primary Topic
- Alcohol Consumption and Health Effects
- Type
- article
- Field-Weighted Citation Impact
- 0.42
Funders
- Zhejiang Chinese Medical University